Citations

Clear

634 citation(s) found for "Hall, A".

UNUSUAL REMISSION AFTER RADIOPHOSPHORUS THERAPY IN A CASE OF "ACUTE PLASMA CELL LEUKEMIA"
Bayrd, Edwin D., Hall, Byron E., Hall, Byron E.

Mayo Clinic

Blood | October 10, 2019 | Volume: 3 | Issue: 9 | Pages: 1019-1024

10.1182/blood.v3.9.1019.1019 Get It

Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.
Raval, Girindra , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Lust, John A., Zeldenrust, Steven R., Hall, Robert L., Hwa, Yi L. , Kapoor, Prashant , Kyle, Robert A. , Gertz, Morie A. , Buadi, Francis K. , Dingli, David , Lin, Yi , Witzig, Thomas E. , Leung, Nelson , Rajkumar, S. Vincent , Dispenzieri, Angela

Mayo Clinic

Blood | October 9, 2019 | Volume: 120 | Issue: 21 | Pages: 946-946

10.1182/blood.v120.21.946.946 Get It

Abstract Abstract 946 Background: The emerging therapies directed at the plasma cell clone have dramatically increased overall survival (OS) for both myeloma and amyloidosis patient populations. As more treatment trials are done in patients (pts) with AL, benchmarks for outcomes among previously treated AL pts are required, especially for those pts who are not candidates for high-dose chemotherapy with peripheral blood stem cell transplantation (ASCT). Inadequate information is available about the number of non-transplant pts who go on to receive second line treatment for AL amyloidosis. Methods: To ascertain the outcomes of pts who did not receive ASCT as primary therapy but who required a second line of therapy, we reviewed the experience of pts seen at Mayo Rochester between 1990 and 2010 according to an IRB approved retrospective review protocol. 1828 pts had their first Mayo visit for AL during this time period. Pts were excluded from this study for the following reasons: 571 had upfront transplant; 907 pts had received only one line of treatment for their amyloid; 91 had longstanding other associated malignancy [Waldenstrom's macroglobulinemia (8), lymphoma (15), CLL (6), multiple myeloma (62)]; and 93 had inadequate follow-up information. One-hundred and sixty-six pts received 2 or more lines of therapy for their AL amyloid and are the subject of these analyses. Statistical analyses were done using JMP statistical software (SAS, Carey, NC). Results: Of the 166 pts, the median age was 64 years (range 34, 84). 49% were male. Baseline organ involvement was as follows: cardiac 84/166 (50%); renal 118/166 (71); liver 23/166 (13.8%); peripheral nerves 19/166 (11.4%); and gastrointestinal 14/166(8.4%). Thirty-one percent (52/16) had both cardiac and renal involvement. Only 73 pts had cardiac biomarkers (NT pro BNP and Troponin T) done at baseline. Of these pts, 26% were stage 1, 49.3% were stage 2, and 24.6% were stage 3 according to original Mayo cardiac biomarker staging system. By inclusion criteria definition, all 166 pts received 1st and 2nd line therapies; 53 (32%) pts received 3rd line of treatment; 20 (12%) received 4th line of treatment; and 10 (6%) received 5th line of treatment. For first line therapy, the most common drugs given either singly or in combination were corticosteroid (147/166; 88.5 %), alkylator (99/166; 59.6%), IMID (34/166; 20.4 %), and bortezomib (19/166; 11.4%). The median time from diagnosis to 2nd line therapy was 10.3 months. Second line regimens received included: corticosteroid, 108/166 (65.1%); alkylator, 76/166 (45.8 %); IMID, 46/166 (27.7%); and bortezomib, 46/166 (27.8%). The median time from diagnosis to 3rd line therapy was 19.8 months. For the 53 pts who received 3rd line treatment, regimens included: corticosteroid, 41/53 (77.3%); IMIDs, 17/53 (32.1%); alkylator, 17/53 (32.1%); bortezomib, 12/53 (22.6%). The median time from diagnosis to 4th line therapy was 31.8 months. For the 20 pts receiving 4th line treatment, regimens included: corticosteroids, 15/20(75%); alkylator, 12/20 (60%), bortezomib, 7/20 (35%); and IMIDs, 4/20(20%). Eighty-three pts have died. The 1 year mortality of our study population was only 8%. The median follow-up of surviving pts was 47.6 months. Figure 1 demonstrates Kaplan-Meier estimates of overall survival (OS) from initiation of each successive therapy. The median OS from initiation of 1st, 2nd, and 3rd lines of treatment were 65, 49.5 and 36.7 months respectively. The median OS after the 4th line of treatment was not reached. The 4 year OS rates from initiation of 1st, 2nd, 3rd and 4th lines of therapy were 58%, 50.8 %, 50 % and 53.4% respectively. Conclusion: Outcomes among relapsed or refractory AL pts are better than what one might expect. Multiple publications have demonstrated that the 1 year mortality of newly diagnosed AL is in the vicinity of 40%. Thereafter, the rate at which pts die dramatically decreases. Our study provides explicit data characterizing the fate of pts unfortunate enough to require additional therapy but fortunate enough to survive past the exceedingly high risk period of death that occurs within 6–12 months of diagnosis. These data provide useful information for benchmarking future trials for treatments of AL amyloidosis. Disclosures: No relevant conflicts of interest to declare.
Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines
Crow, Lauren , Jambusaria‐Pahlajani, Anokhi , Chung, Christina Lee , Baran, David A. , Lowenstein, Stefan E. , Abdelmalek, Mark, Ahmed, Rehana L. , Anadkat, Milan J. , Arcasoy, Selim M. , Berg, Daniel , Bibee, Kristin , Billingsley, Elizabeth M. , Black, William H., Blalock, Travis W. , Bleicher, Melissa, Brennan, Daniel C. , Brodland, David G., Brown, Mariah , Carroll, Bryan T. , Carucci, John A. , Chang, Timothy W., Chaux, George, Cusack, Carrie Ann, Dilling, Daniel F. , Doyle, Alden , Emtiazjoo, Amir , Ferguson, Nkanyezi H., Fosko, Scott W. , Fox, Matthew C., Göral, Simin , Gray, Alice , Griffin, John R., Hall, Shelley , Hanlon, Allison , Hayes, Don , Hickey, Gavin , Holtz, Jonathan E., Hopkins, R. Samuel, Hu, Jenny, Huang, Conway C. , Kapnadak, Siddhartha G. , Kraus, Edward S., Leitenberger, Justin J. , Lim, Mary Ann , Longo, María Isabel , Malik, Shahid M. , Menter, Alan , Myers, Sarah A., Neuburg, Marcy, Nijhawan, Rajiv I. , Norman, Douglas J., Otley, Clark C. , Paek, So Yeon , Parulekar, Amit , Patel, Manisha J., Patton, Timothy , Pugliano‐Mauro, Melissa , Ranganna, Karthik, Redenius, Rachel, Samie, Faramarz H. , Shin, Thuzar M. , Singer, Jonathan P. , Singh, Pooja , Soon, Seaver L. , Squires, Ronald A., Stasko, Thomas, Stein, Jennifer , Taler, Sandra J. , Thomas, Christie P. , Tokman, Sofya , Tomic, Rade , Twigg, Amanda R. , Wigger, M., Zeitouni, Nathalie C., Crow, Lauren D , Leca, Nicolae , Mallea, Jorge M. , Tomic, Rade , Singer, Jonathan P , Baran, David A , Paek, So Yeon , Ferguson, Nkanyezi , Hachem, Ramsey R. , Jiang, Shang I. Brian , Lease, Erika D. , Lee, James , Patel, Vishal Anil , Ravichandran, Ashwin Kumar , Redenius, Rachel A., Roll, Garrett Richard , Soriano, Teresa T. , Terrault, Norah A. , Arron, Sarah T. , Thomas, Christie P

Mayo Clinic

Transplant International | September 10, 2019 | Volume: 32 | Issue: 12 | Pages: 1268-1276

10.1111/tri.13520 | PMID 31502728 Get It

ESRA19-0430 Latex DYE confirmation of local anesthetic spread in pericapsular nerve group (PENG) block
Hall, Jason, Clendenen, Steven R.

Mayo Clinic

E-Poster Viewing Abstracts | August 30, 2019 | Volume: No volume available | Issue: No issue available | Pages: A213.2-A214

10.1136/rapm-2019-esraabs2019.371 Get It

Abstract 962: Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries
Choudhury, Parichoy Pal , Wilcox, Amber, Gao, Chi , Brook, Mark N. , Martin, Kara, Schoemaker, Minouk J. , Chang‐Claude, Jenny , Easton, Doug , Vachon, Celine M. , Kaaks, Rudolph, Gaudet, Mia M. , Antoniou, Antonis C. , Chatterjee, Nilanjan , Schoemaker, Minouk J , Wilcox, Amber, Carter, Brian, Hüsing, Anika , Eriksson, Mikael , Scott, Christopher G. , Shi, Min Yan , Ahearn, Thomas U. , Jones, Michael E. , Orr, Nick , Czene, Kamila , Simard, Jacques , Easton, Douglas F. , Schmidt, Marjanka K. , Sandler, Dale P. , Weinberg, Clarice R. , Vachon, Celine M. , Milne, Roger L. , Hall, Per N , Swerdlow, Anthony J. , Kraft, Peter , García‐Closas, Montserrat

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 962-962

10.1158/1538-7445.am2019-962 Get It

Abstract Background: Prospective validation of breast cancer risk models integrating classical risk factors and genetic variants is required for risk-stratified prevention and screening strategies. The objective of this study was to validate a breast cancer risk model integrating classical risk factors and a 313-variant polygenic risk score (PRS) in multiple prospective cohort studies, and to project five-year risk of breast cancer in six different countries. Methods: The study population included 7,529 cases and 230,103 controls from 14 prospective cohort studies in Australia, Germany, the Netherlands, Sweden, UK, and USA. We used the Individualized Coherent Absolute Risk Estimator (iCARE) tool for risk model building, validation, and risk projection. Expected five-year risk of invasive or in situ breast cancer was compared to observed risk, overall and within deciles of expected risk using goodness of fit statistics. We evaluated calibration of the relative risk through meta-analysis across cohorts, and of the absolute risk within each cohort. Model discrimination was evaluated using the area under the curve (AUC), and percentages of women crossing risk thresholds. Projections of five-year risk distributions were estimated for women of European ancestry aged 50-70 years in the general populations of these six countries. Results: Analysis showed overall good calibration of the integrated iCARE-based model relative risk for both women younger than 50 years (χ2=14.9, P=0.09) and aged 50 years or older (χ2=14.6, P=0.10), with a small overestimation of risk for women in the highest decile of expected risk (RR = 3.5 expected vs 2.3 (95% CI 1.6 to 3.2) observed for women <50 years; and 2.8 expected vs 2.3 (95% CI 2.0 to 2.7) observed for women 50+ years). The age-adjusted AUCs for the integrated model were 63.1 (95% CI 60.9 to 65.3) and 62.9 (95% CI 61.8 to 64.0), for the two age groups respectively. The calibration of absolute risk showed substantial variation across cohorts, particularly for the older group, but had no systematic bias. Model based projections in the general populations showed that compared to the population average, women in the 1st and 99th percentiles of the integrated risk score had relative risks 0.19 and 3.56 respectively. The proportion of women of European ancestry aged 50-70 years with a five-year risk greater than 3% (threshold for consideration of risk-lowering drugs by U.S. Preventive Services Task Force) ranged from 7.1% in Germany to 18.2% in the US, which corresponds to ~5.5 million women in the US. Conclusions: Five-year risk predictions from a model with classical risk factors and PRS are well calibrated and provide substantial risk stratification across multiple cohorts in six different countries. Further studies are needed to evaluate the clinical utility of the validated model for risk stratified screening and prevention of breast cancer. Citation Format: Parichoy Pal Choudhury, Amber Wilcox, Chi Gao, Brian Carter, Anika Husing, Mark Brook, Mikael Eriksson, Kara Martin, Chris Scott, Min Shi, Thomas Ahearn, Michael Jones, Nick Orr, Minouk Schoemaker, Kamila Czene, Jenny Chang-Claude, Jacques Simard, Doug Easton, Marjanka K. Schmidt, Dale Sandler, Clarice R. Weinberg, Celine Vachon, Roger Milne, Per Hall, Anthony Swerdlow, Rudolph Kaaks, Myrto Barrdahl, Mia Gaudet, Antonis Antoniou, Peter Kraft, Montserrat Garcia-Closas, Nilanjan Chatterjee. Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 962.
Abstract 873: Molecular mechanisms of non-small cell lung cancer growth and drug resistance
Astone, Matteo , Liu, Ping , Coyle, Abbygail M. , Dankert, Erin N. , Hoffman, Dane K. , Hall, Stephanie R., Kuang, Rui , Roden, Anja C. , Alam, Sk. Kayum , Wang, Li , Zhang, Wei , Mansfield, Aaron S. , Hoeppner, Luke H.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 873-873

10.1158/1538-7445.am2019-873 Get It

Abstract Lung cancer is the deadliest and most frequently diagnosed type of tumor worldwide, with 1.6 million deaths reported annually. Non-small cell lung cancer (NSCLC) represents 85% of all lung cancer cases and carries a poor 5-year survival rate below 15%. Prognoses remain dismal due to the large number of patients diagnosed with advanced stage disease and the development of resistance to current therapies. A better understanding of acquired drug resistance will help to circumvent the progression of lung cancer and make significant strides in improving NSCLC patient treatment. Our recent work demonstrates that dopamine and cAMP-regulated phosphoprotein, Mr 32000 (DARPP-32) and its amino-terminally truncated splice variant (t-DARPP) promote lung tumor growth in orthotopic mouse models. IHC staining of 62 human lung adenocarcinoma tissues showed that t-DARPP expression is elevated with increasing tumor (T) staging score, which represents the size of the primary tumor and whether it has grown into nearby areas, as a metric of tumor progression and growth. Correspondingly, a computational biology analysis of 513 lung adenocarcinoma patients revealed upregulation of t-DARPP isoform expression correlates with advanced T stage and is associated with poor overall survival. We identified a novel physical interaction between DARPP-32 and inhibitory kappa B kinase-α (IKKα) that promotes NSCLC cell migration through activation of non-canonical NF-κB2 signaling. It has been shown that DARPP-32 overexpression inhibits gefitinib-induced apoptosis in gastric cancer and t-DARPP contributes to the trastuzumab resistance phenotype in breast cancer. Our recent findings suggest DARPP-32 and t-DARPP overexpression in NSCLC promotes resistance to specific molecular targeted inhibitors by enabling tumor cells to evade apoptosis via Akt- and Erk-dependent cell survival mechanisms. Current ongoing studies are focused on manipulating expression of DARPP-32 isoforms in lung tumor cells to prevent resistance to targeted therapies in NSCLC patients. Citation Format: SK Kayum Alam, Matteo Astone, Ping Liu, Li Wang, Abbygail M. Coyle, Erin N. Dankert, Dane K. Hoffman, Stephanie R. Hall, Wei Zhang, Rui Kuang, Anja C. Roden, Aaron S. Mansfield, Luke H. Hoeppner. Molecular mechanisms of non-small cell lung cancer growth and drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 873.
Impact of Poetry on Empathy and Professional Burnout of Health-Care Workers: A Systematic Review
Schoonover, Kimberly , Hall‐Flavin, Daniel K., Whitford, Kevin J. , Lussier, Mark, Essary, Alison C. , Schoonover, Kimberly L, Hall-Flavin, Daniel, Whitford, Kevin, Lapid, Maria I.

Mayo Clinic

Journal of Palliative Care | July 29, 2019 | Volume: 35 | Issue: 2 | Pages: 127-132

10.1177/0825859719865545 | PMID 31354038 Get It

Background: Narrative medicine (NM) interventions have positively influenced empathy and burnout to varying degrees in health-care workers. We systematically reviewed the impact of poetry, a form of NM, on empathy and professional burnout. Methods: A comprehensive search of Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, and Daily, Ovid EMBASE, Ovid PsycINFO, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus, from inception to September 25, 2018, for articles published in English, was conducted using search terms related to NM, empathy, professional burnout, and health-care personnel. Results: Of the 401 abstracts independently screened for inclusion by 2 reviewers, 2 quantitative, 3 qualitative studies, and 1 research letter were included. One research letter, focusing on the use of poetry, found it to increase empathy as measured by a nonvalidated questionnaire. All other studies used mixed NM interventions: 2 quantitative studies, using validated surveys, showed an increase in empathy and 2 qualitative studies showed limited to a prominent finding of increased empathy. There were no studies that used poetry exclusively to assess impact on professional burnout. One quantitative study, utilizing a validated survey, revealed no overall reduced burnout among residents, although high attendance participants had moderately reduced burnout postintervention, and one qualitative study noted limited reduction in burnout. Conclusion: There is evidence that poetry as part of a NM intervention may increase empathy and limited evidence that it may reduce professional burnout among health-care workers.
A Prospective Multicenter Study Evaluating Endoscopy Competence Among Gastroenterology Trainees in the Era of the Next Accreditation System
Han, Samuel , Obuch, Joshua , Duloy, Anna , Keswani, Rajesh N. , Simon, Violette C., Ezekwe, Eze, Menard‐Katcher, Paul , Patel, Swati , Aagard, Eva, Brimhall, Bryan , Ahmad, Asyia, Broy, Charles, Carlin, Linda, Connolly, Seán , Cooley, David , Cowley, Kevin, Palma, Jack A. Di, Early, Dayna S., Ellert, Swan , Gaumnitz, Eric A., Ghassemi, Kevin A., Lebovics, Edward, Lee, Robert , Lunsford, Tisha , Massaad, Julia , Mittal, Mohit , Morigeau, Kirsten, Pietrak, Stanley, Piper, Michael , Shah, Anand S. , Shapiro, Alan, Sonnier, William, Sorrell, Cari, Vignesh, Shivakumar , Woolard, Shani, Wani, Sachin , Hall, Matt , Alghamdi, Saad Ali , Brown, Michael D. , Chugh, Priyanka , Connolly, Sean E., Cooley, D. Matthew

Mayo Clinic

Academic Medicine | July 21, 2019 | Volume: 95 | Issue: 2 | Pages: 283-292

10.1097/acm.0000000000002885 | PMID 31335810 Get It

Purpose The Next Accreditation System requires training programs to demonstrate competence among trainees. Within gastroenterology (GI), there are limited data describing learning curves and structured assessment of competence in esophagogastroduodenoscopy (EGD) and colonoscopy. In this study, the authors aimed to demonstrate the feasibility of a centralized feedback system to assess endoscopy learning curves among GI trainees in EGD and colonoscopy. Method During academic year 2016–2017, the authors performed a prospective multicenter cohort study, inviting participants from multiple GI training programs. Trainee technical and cognitive skills were assessed using a validated competence assessment tool. An integrated, comprehensive data collection and reporting system was created to apply cumulative sum analysis to generate learning curves that were shared with program directors and trainees on a quarterly basis. Results Out of 183 fellowships invited, 129 trainees from 12 GI fellowships participated, with an overall trainee participation rate of 72.1% (93/129); the highest participation level was among first-year trainees (90.9%; 80/88), and the lowest was among third-year trainees (51.2%; 27/53). In all, 1,385 EGDs and 1,293 colonoscopies were assessed. On aggregate learning curve analysis, third-year trainees achieved competence in overall technical and cognitive skills, while first- and second-year trainees demonstrated the need for ongoing supervision and training in the majority of technical and cognitive skills. Conclusions This study demonstrated the feasibility of using a centralized feedback system for the evaluation and documentation of trainee performance in EGD and colonoscopy. Furthermore, third-year trainees achieved competence in both endoscopic procedures, validating the effectiveness of current training programs.
Factors Associated with Cigarette Use During Airmen’s First Year of Service in the United States Air Force
Little, Melissa A. , Ebbert, Jon O. , Krukowski, Rebecca A. , Halbert, Jennifer P. , Kalpinski, Maj Ryan, Talcott, G. Wayne , Klesges, Robert C. , Patten, Christi A.

Mayo Clinic

Military Medicine | July 9, 2019 | Volume: 185 | Issue: 1-2 | Pages: e212-e220

10.1093/milmed/usz155 | PMID 31287888 Get It

Abstract Introduction Despite declines of cigarette use in the civilian population, military personnel report alarmingly high rates of cigarette use. Enlisted Air Force recruits are required to remain tobacco-free for the first 12 weeks of training, and the majority express confidence they will not use tobacco after the ban; however, most previous smokers return to smoking and many nonsmokers initiate. Understanding the factors associated with cigarette-smoking initiation among non-users and re-initiation among former users is critical for the development of successful tobacco control efforts. Materials and Methods The current study examines predictors of cigarette smoking among a sample of 2,188 USAF personnel after their first year of service. Logistic regression analyses examined associations between baseline predictors and initiation and re-initiation of cigarette smoking at a one-year follow-up. Results Compared to never smokers at both time points, the strongest predictor of smoking initiation over the past 12 months was having owned cigarette-branded merchandise (OR 3.81, 95% CI 1.67, 8.71). Compared to former smokers who remained abstinent, the strongest predictor of re-initiation was intention to use tobacco (OR 2.08, 95% CI 1.53, 2.83). Compared to individuals who initiate, the strongest predictors of re-initiation were prior use of other tobacco products and tobacco use intentions (ORs range 1.85 to 4.63). Conclusions Multiple risk factors are associated with tobacco use. Given that Airmen are tobacco-free for the first 12 weeks of training, tobacco interventions during this period might be more effective. Our findings can be used to tailor interventions to prevent tobacco use in the U.S. military.